CIVATECH ONCOLOGY, INC.
Morrisville, NC · Founded 2006 · CIK 0001373884 · Medtech · Private
CivaSheet® – an implantable radioactive brachytherapy device delivering localized radiation therapy directly to tumors
civatechoncology.com →- Grants
- $11M
- 12 awards
- Sector median: 1
- Raised
- $12M
- 12 Form D · Nov 2021
- 59 months since last filing
- Contracts
- $1.2M
- 2 awards · Health and Human S
- #292 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2008201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $1,500 | |
| Private capital raised | Form D · SEC | $115,000 | |
| Federal contract | Department of Health and Human Services · TAS::75 0849::TAS | $199,266 | |
| Private capital raised | Form D · SEC | $175,000 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Other Functions "development Of A Uni-directional Brachytherapy Device For The Treatment Of Non-small-cell Lung Cancer" | $995,343 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Private capital raised | Form D · SEC | $320,000 | |
| Private capital raised | Form D · SEC | $1,630,001 | |
| Private capital raised | Form D · SEC | $10,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $299,599 | |
| Private capital raised | Form D · SEC | $916,134 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $1,464,585 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $296,866 | |
| Private capital raised | Form D · SEC | $15,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers | $570,035 | |
| Federal grant | Department of Health and Human Services · Phase II · Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $2,188,488 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $1,165,750 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $801,730 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $595 | |
| Federal grant | Department of Health and Human Services · Phase II · Administrative Supplement for the Evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer | $220,413 | |
| Private capital raised | Form D · SEC | $7,939,016 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercializing CivaSheet for Pancreatic Cancer Patients | $1,864,846 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercializing CivaSheet for Pancreatic Cancer Patients | $1,117,042 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercializing CivaSheet for Pancreatic Cancer Patients | $1,017,318 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 289 | Cheetah Medical | $1.2M | $40M |
| 290 | Genalyte | $1.2M | — |
| 291 | electroCore, Inc. | $1.2M | $52M |
| 292 | CIVATECH ONCOLOGY, INC. | $1.2M | $12M |
| 293 | CLEAR GUIDE MEDICAL, INC. | $1.2M | $25K |
| 294 | CLEAR GUIDE MEDICAL, LLC | $1.2M | $3.6M |
| 295 | BIOFLUIDICA, INC. | $1.2M | $13M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Suzanne BabcockDirector · Executive Officer
- SUZANNE BABCOCKDirector
- James BeckDirector
- Robert BlackDirector · Executive Officer
- Claudia BlackExecutive Officer
- CLAUDIA BLACKExecutive Officer
- ROBERT BLACKDirector · Executive Officer
- Delwin CoufalDirector
- Robert GreczynDirector
- Robert Greczyn, Jr.Director
- Herb KuhnDirector
- Tempe LampeDirector · Executive Officer
- Jeremy MarioDirector
- JEREMY MARIODirector
- Carlton MidyetteDirector
- William PullyDirector
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.